Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Jordi Remón, Jean‐Charles Soria, Solange Peters
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1637-1642
Open Access | Times Cited: 272

Showing 26-50 of 272 citing articles:

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Roy S. Herbst, Thomas John, Christian Grohé, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
Paul Hofman, Fiorella Calabrese, Izidor Kern, et al.
ESMO Open (2023) Vol. 8, Iss. 5, pp. 101628-101628
Open Access | Times Cited: 18
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 2, pp. 199-215
Open Access | Times Cited: 18
The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges
Qiuyuan Hu, Ke Li, Conghui Yang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 16
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 7
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC
Tae Hee Hong, Soohyun Hwang, Abhijit Dasgupta, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1512-1524
Closed Access | Times Cited: 6
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
Thomas John, Christian Grohé, Jonathan W. Goldman, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 9, pp. 1209-1221
Open Access | Times Cited: 16
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review
Collin M. Blakely, Walter Weder, Lukas Bubendorf, et al.
Lung Cancer (2023) Vol. 177, pp. 59-72
Closed Access | Times Cited: 14
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 7, pp. 1779-1789
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1410-1410
Open Access | Times Cited: 5
New developments in the imaging of lung cancer
Ádám Domonkos Tárnoki, Dávid László Tárnoki, Marta Dąbrowska, et al.
Breathe (2024) Vol. 20, Iss. 1, pp. 230176-230176
Open Access | Times Cited: 5
Recent advances to address challenges in extracellular vesicle-based applications for lung cancer
Gaigai Huang, Wenshu Zheng, Yu Zhou, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3855-3875
Open Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
Ilias Houda, Idris Bahce, Chris Dickhoff, et al.
Lung Cancer (2024) Vol. 199, pp. 108061-108061
Open Access | Times Cited: 5
Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review
Katarzyna Król, Artur Mazur, Paulina Stachyra‐Strawa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5858-5858
Open Access | Times Cited: 12
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
Dong‐Wan Kim, Byoung Chul Cho, Krishna Pachipala, et al.
Lung Cancer (2024) Vol. 190, pp. 107530-107530
Open Access | Times Cited: 4
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Fabrice Barlési, Byoung Chul Cho, Sarah B. Goldberg, et al.
Future Oncology (2024) Vol. 20, Iss. 29, pp. 2137-2147
Open Access | Times Cited: 4
Advancing Thoracic Surgical Oncology in the Era of Precision Medicine
Giacomo Argento, Erino Angelo Rendina, Giulio Maurizi
Cancers (2025) Vol. 17, Iss. 1, pp. 115-115
Open Access
FAM83A-AS1 predicts severe development of non-small cell lung cancer and adverse postoperative prognosis of thoracotomy
Feng Tang, Yuemian Liang, Li-Cai Zhang, et al.
Journal of Cardiothoracic Surgery (2025) Vol. 20, Iss. 1
Open Access
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study
Giannis Mountzios, Sofia Lampaki, Helena Linardou, et al.
Future Oncology (2025), pp. 1-16
Closed Access
Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer
Paul Hofman, Petros Christopoulos, Nicky D’Haene, et al.
Lung Cancer (2025), pp. 108107-108107
Closed Access
Efficacy and Safety of Immune Checkpoint Inhibition Combined with Concurrent Chemoradiotherapy in Patients with Stage III Unresectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Fabian Acker, Martin Reck, Daniel Martín, et al.
European Journal of Cancer (2025) Vol. 218, pp. 115266-115266
Open Access
The Application of Rapid Ultrasound-Guided Paraffin Technique in the Pathological Examination of Biopsy Specimens from Non-Small Cell Lung Cancer
Li Zhu, Jing‐Jing Yang, Wei Xia, et al.
(2025)
Closed Access
NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives
Kareem S. Tahayneh, Mayar Idkedek, Firas Abu Akar
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1025-1025
Open Access
Development and validation of a nomogram model for predicting lymph node metastasis in early non-small-cell lung cancer
Hao Xie, Chao Wang, Lin Ma, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 1, pp. 299-310
Closed Access

Scroll to top